Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush

William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'

William Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)

The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).... More

Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel

Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $39.00) while maintaining a Buy rating.... More

Wells Fargo Upgrades Viridian Therapeutic (VRDN) to Overweight

Wells Fargo analyst Derek Archila upgraded Viridian Therapeutic (NASDAQ: VRDN) from Equal Weight to Overweight with a price target of $31.00.

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $17.90 yesterday.

Truist Reiterates Buy Rating on Viridian Therapeutic (VRDN) Following Veligrotug's FDA approval

Truist Securities analyst Greg Renza reiterated a Buy rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

The analyst commented: "Aloha Lumvoa: FDA Approval & Pieces in Place Welcome VRDN's First Commercial Asset to the Thyroid Eye Market; Veligrotugs FDA approval on Friday evening, arriving ahead of its June 30th PDUFA, marks the defining inflection... More

UBS Reiterates Buy Rating on Viridian Therapeutic (VRDN)

UBS analyst Michael Yee reiterated a Buy rating and $50.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

The analyst commented, "VRDN announced Lumvoa (previously named veligrotug) is now approved in both active and chronic TED as expected, based on positive data from both THRIVE-1 and THRIVE-2. This is the IV... More

Comcast, Viridian Therapeutics jump premarket; Doximity slips

Investing.com - U.S. stock futures rose on Monday as investors assessed reports that Washington and Tehran had agreed to halt recent hostilities around the Strait of Hormuz and resume diplomatic talks, easing fears of broader disruptions in the Middle East.

By 07:39 ET, S&P 500 Futures had gained 0.65%, Nasdaq 100 Futures had climbed 1.16%, and Dow Jones Futures had advanced 0.43%.

Technology and healthcare stocks led premarket gains, while investors... More

H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $22.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

The analyst commented: "On Friday, Viridian announced that FDA approved veligrotug, now with the brand name Lumvoa, for the treatment of thyroid eye disease (TED).... More

Viridian Therapeutic (VRDN) Reiterated at Market Outperform by Citizens: Lumvoa Approved

Citizens analyst Jason Butler reiterated a Market Outperform rating and $35.00 price target on Viridian Therapeutic (NASDAQ: VRDN).

The analyst commented, "Lumvoa (veli) approved by FDA with the expected differentiated label; we reiterate our Market Outperform rating and $35 risk-adjusted, DCF-derived price target on Viridian... More

FDA approves Viridian's Lumvoa for thyroid eye disease

Viridian Therapeutics (Nasdaq: VRDN) announced that the U.S. Food and Drug Administration has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED), a rare autoimmune condition that can cause inflammation around and behind the eyes, leading to proptosis, diplopia, pain, and vision impairment.

Lumvoa, a full antagonist of IGF-1R, is administered as five intravenous infusions over 12 weeks. The FDA granted the... More